Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CFO Scott Burrows sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $95.57, for a total transaction of $716,775.00. Following the transaction, the chief financial officer owned 97,994 shares in the company, valued at approximately $9,365,286.58. This trade represents a 7.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Price Performance

SYRE stock opened at $104.35 on Thursday. The company has a fifty day moving average price of $89.91 and a 200 day moving average price of $64.66. Spyre Therapeutics, Inc. has a 12 month low of $14.51 and a 12 month high of $108.14. The company has a market cap of $9.18 billion, a price-to-earnings ratio of -53.51 and a beta of 3.03.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.40. As a group, analysts anticipate that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on SYRE. Deutsche Bank Aktiengesellschaft raised their price target on Spyre Therapeutics from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. Wall Street Zen downgraded Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Wolfe Research cut Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Thursday, June 4th. Finally, Leerink Partners boosted their target price on Spyre Therapeutics from $49.00 to $106.00 and gave the company an “outperform” rating in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spyre Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $110.15.

More Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Spyre reported a second-quarter loss of $0.36 per share, substantially narrower than the analyst consensus estimate of $0.76. The earnings beat suggests better-than-expected cost management and helped improve investor sentiment. SYRE’s Q2 Loss Narrower Than Expected, Pipeline Progresses
• Positive Sentiment: The company highlighted progress across its Phase 2 development pipeline and upcoming clinical data readouts. These catalysts are particularly important for Spyre because the company remains focused on advancing its therapies rather than generating near-term profits. Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Wedbush raised its price target from $100 to $130 and maintained an “Outperform” rating. Guggenheim also increased its target from $115 to $130 and kept a “Buy” rating, signaling that analysts see additional upside from Spyre’s pipeline and upcoming clinical milestones. Analyst price-target updates

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SYRE. GAMMA Investing LLC raised its stake in shares of Spyre Therapeutics by 26.8% during the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after buying an additional 140 shares in the last quarter. Optimize Financial Inc boosted its stake in shares of Spyre Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock valued at $830,000 after buying an additional 364 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Spyre Therapeutics by 0.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after buying an additional 522 shares in the last quarter. Summit Securities Group LLC acquired a new position in Spyre Therapeutics during the first quarter worth $28,000. Finally, California State Teachers Retirement System grew its holdings in Spyre Therapeutics by 1.8% during the second quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after acquiring an additional 603 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.